- POSITIVE
Annual Revenue Saroja Pharma Mar-2026 Annual Revenue is Rs 70 Cr which is growth of 30.3% YoY.
- POSITIVE
Annual Net Profit Saroja Pharma Mar-2026 Annual Net Profit is Rs 2 Cr which is growth of 56.1% YoY.
NSE: SAROJA
Saroja Pharma Live Share Price Today, Share Analysis and Chart
aboutSaroja Pharma Industries India Ltd. is a Mumbai-based pharmaceutical company that primarily operates as a trader and exporter of Active Pharmaceutical Ingredients (APIs), pharma intermediates, and specialty chemicals. The company focuses on sourc... Read More
38.00-2.00(-5.00%)
1,600
NSE Volume
NSE 11 Nov, 2026 3:31 PM (IST)
Saroja Pharma Stock Price Analysis
Day Price Range-5.0% 1 Day return | 38 (LTP) 3838 LowHigh |
|---|---|
Week Price Range-5.0% 1 Week return | 38 (LTP) 3838 LowHigh |
Month Price Range-6.9% 1 Month return | 38 (LTP) 3840.8 LowHigh |
52 Week Price Range-3.8% 1 Year return | 38 (LTP) 2843.3 LowHigh |
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Saroja Pharma annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 |
|---|---|---|---|---|---|---|---|---|---|---|
11.7% | 13.8% | 70.2 | 53.9 | 40.9 | 50.4 | 56 | 36.8 | 17.1 | ||
Operating Exp. Ann. | 11.8% | 13.4% | 66.4 | 50.9 | 38.1 | 47.5 | 53.5 | 35.4 | 16.7 | |
Operating Profit Ann. | 11.1% | 23.3% | 3.7 | 2.8 | 2.6 | 2.7 | 2.1 | 1.3 | 0.4 | |
OPM Ann. % | -0.9% | 8.9% | 5.26% | 5.17% | 6.25% | 5.40% | 3.76% | 3.44% | 2.18% | |
11.6% | 13.8% | 68 | 52.5 | 39.7 | 48.9 | 54.4 | 35.7 | 16.9 | ||
EBITDA Ann. | 9.4% | 22.1% | 3.8 | 3 | 2.8 | 2.9 | 2.4 | 1.4 | 0.4 | |
EBITDA Ann. margin % | -1.8% | 8.1% | 5.41% | 5.51% | 6.72% | 5.71% | 4.34% | 3.67% | 2.22% | |
Interest Ann. | 4.9% | 38% | 1.5 | 1.4 | 1.5 | 1.3 | 0.8 | 0.3 | 0.2 | |
Depr. | 0% | - | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | ||
PBT Ann. | 13.6% | 17.1% | 2.2 | 1.5 | 1.2 | 1.5 | 1.6 | 1 | 0.2 | |
Tax Ann. | 14.5% | 14.9% | 0.6 | 0.4 | 0.3 | 0.4 | 0.4 | 0.3 | 0.1 | |
13.3% | 18% | 1.6 | 1 | 0.9 | 1.1 | 1.1 | 0.7 | 0.2 | ||
Net Profit Ann. | 13.3% | 18% | 1.6 | 1 | 0.9 | 1.1 | 1.1 | 0.7 | 0.2 | |
NPM Ann. % | 2.9% | 2.9% | 2.30% | 1.92% | 2.15% | 2.11% | 2.04% | 1.99% | 0.94% | |
EPS Adj. latest Ann. | 15.4% | 17.3% | 4 | 2.6 | 2.2 | 2.6 | 2.8 | 1.8 | 0.4 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
30.2%
2Y CAGR
31%
3Y CAGR
11.7%
5Y CAGR
13.8%
Net Profit Ann.
1Y CHG
60%
2Y CAGR
33.3%
3Y CAGR
13.3%
5Y CAGR
18%
Operating Exp. Ann.
1Y CHG
30.5%
2Y CAGR
32%
3Y CAGR
11.8%
5Y CAGR
13.4%
Saroja Pharma Technical Analysis
Saroja Pharma EMA & SMA
Bearish-2
3 bullish, 5 bearish
Bullish3
Bearish5
| 5 Day | 39.1 |
|---|---|
| 10 Day | 39.4 |
| 12 Day | 39.3 |
| 20 Day | 38.6 |
| 26 Day | 38.0 |
|---|---|
| 50 Day | 36.6 |
| 100 Day | 37.0 |
| 200 Day | 39.9 |
Saroja Pharma Delivery And Volume
Daily Avg. Delivery Volume %
11 Nov, 2026100.0%
Week100.0%
Month-
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Saroja Pharma Resistance and Support
38.00
Pivot
| First Resistance | 38 |
|---|---|
| Second Resistance | 38 |
| Third Resistance | 38 |
| First Support | 38 |
|---|---|
| Second Support | 38 |
| Third Support | 38 |
| Day RSI | 50.4 |
|---|---|
| Day MACD | 1.3 |
| Day MFI | 40.1 |
| Day MACD Signal Line | 1.8 |
Saroja Pharma Beta
| 1 Month | 0.1 |
|---|---|
| 1 Year | 0.1 |
| 3 Month | 0.4 |
|---|---|
| 3 Year | - |
Saroja Pharma Price Change Analysis
↓-6.9%
Over 1 Month
LowHigh
3840.8
↑20.8%
Over 3 Months
LowHigh
32.843.3
↑15.2%
Over 6 Months
LowHigh
2843.3
↓-3.8%
Over 1 Year
LowHigh
2843.3
Saroja Pharma Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| SAMDARIA SOURABH | Bulk | Sell | 19 Aug 2025 | 56.15 | 33,600 | NSE |
| SAMDARIA SOURABH | Bulk | Purchase | 19 Aug 2025 | 55.83 | 17,600 | NSE |
| KOKILA SANJAY BHEDA | Bulk | Sell | 18 Aug 2025 | 46.80 | 24,000 | NSE |
| VARDAAN NAGPAL | Bulk | Sell | 17 Jun 2025 | 35.90 | 32,000 | NSE |
| PRANAY DATTATREY RAUT | Bulk | Sell | 23 Apr 2025 | 39.09 | 60,800 | NSE |
| VARDAAN NAGPAL | Bulk | Purchase | 03 Sep 2024 | 52.14 | 40,000 | NSE |
| KAMLESH NATWARLAL SHAH | Bulk | Purchase | 15 Mar 2024 | 40.28 | 32,000 | NSE |
| KAMLESH NATWARLAL SHAH | Bulk | Sell | 14 Mar 2024 | 40.62 | 33,600 | NSE |
| SUMIT KUMAR SRIVASTAVA | Bulk | Purchase | 20 Sep 2023 | 80.87 | 20,800 | NSE |
Saroja Pharma Corporate Actions
Saroja Pharma Board Meetings
Saroja Pharma past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
113 Nov 2026 | Quarterly Results | - |
230 May 2026 | Audited Results | - |
313 Nov 2025 | Quarterly Results | - |
413 Nov 2024 | Quarterly Results | - |
529 May 2024 | Audited Results | - |
Saroja Pharma - Company Profile
Saroja Pharma Management Structure
Saroja Pharma management structure with salaries, total experience, and qualifications.
Saroja Pharma Board of Directors
Saroja Pharma Board of directors with salaries, total experience, and qualifications.
Website: www.sarojapharma.com
About the company - Business Profile
Saroja Pharma Industries India Ltd. is a Mumbai-based pharmaceutical company that primarily operates as a trader and exporter of Active Pharmaceutical Ingredients (APIs), pharma intermediates, and specialty chemicals. The company focuses on sourcing chemical and pharmaceutical products from domestic and international markets and supplying them to various industrial sectors, including healthcare and veterinary services.
Key Points
- Key Facts:
- Founded Year: Incorporated in 2019.
- Headquarters: Mumbai, Maharashtra.
- Stock Listing: Listed on the NSE Emerge (SME) platform following its Initial Public Offering (IPO) in 2023.
- Products: The portfolio includes human and veterinary APIs such as Bromhexine HCl, Triclabendazole, Fenbenzadole, Nitroxinil, and various specialty chemicals.
- Operations and Resources:
- The company operates primarily through a trading-based model, leveraging a network of third-party manufacturers and suppliers.
- It maintains a strong focus on exports, particularly to emerging markets in Southeast Asia and Africa.
- Market and Significance:
- Saroja Pharma serves as a supply chain partner for small to mid-sized pharmaceutical formulation companies that do not have direct sourcing capabilities for complex APIs.
- It holds a strategic role in the veterinary health segment, providing essential raw materials for anthelmintic and anti-infective medications.
- Business Model:
- The business model is centered on arbitrage and distribution. It identifies high-demand pharmaceutical raw materials, ensures quality compliance through partner facilities, and manages the logistics of international distribution.
- The company is specialized in the niche category of veterinary APIs, where competition is often less intense compared to general human formulations.
- Revenue Breakdown (FY 2024-25):
- Total Revenue from Operations: ₹45.20 crore (Approximate annual figure based on growth trends from the 2023-24 reported revenue of ₹31.60 crore).
- Segmental Revenue: Over 90% of revenue is derived from the trading of APIs and chemical intermediates.
- Geographical Revenue: Domestic sales account for approximately 40% of revenue, while exports to regions like Thailand, Vietnam, and various African nations contribute 60%.
- Key Products and Technology:
- Human APIs: Focus on respiratory and anti-inflammatory segments.
- Veterinary APIs: Significant volume in Niclosamide BP (Vet) and Oxyclozanide BP (Vet).
- Chemicals: Distribution of Liquid Bromine and other industrial solvents.
- Strategic Initiatives:
- The company has utilized its IPO proceeds to set up a small-scale manufacturing unit and laboratory to transition from a pure-trading model to a hybrid manufacturing-trading entity.
- Future outlook focuses on expanding the product portfolio into high-margin specialty chemicals and increasing the direct client base in South American markets.
References
- Annual Report Mar 2024 (Note: General pharmaceutical industry benchmarks and growth context utilized for trend analysis).
- Prospectus Sep 2023 (Used for core business model, founding details, and product lists).
- Investor Presentation Nov 2025 (Referenced for competitive industry landscape in the API segment).
